New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...
Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.
Oral Solid Dosage Pharmaceutical Formulation Market is projected to achieve US$ 8,95,636.0 million by 2034 at a CAGR of 3.7%.